Eli Lilly, AC Immune Ink Alzheimer's Collaboration -- Update
12 Dezembro 2018 - 10:19AM
Dow Jones News
By Colin Kellaher
Eli Lilly & Co. (LLY) and AC Immune SA (ACIU) on Wednesday
said they agreed to collaborate on potential treatments for
Alzheimer's and other neurodegenerative diseases in a deal that
could be worth billions of dollars to AC Immune.
The companies said the collaboration will focus primarily on AC
Immune's lead molecule, ACI-3024, and will combine AC Immune's
proprietary Morphomer platform technology with Eli Lilly's clinical
development and commercial capabilities in central nervous system
disorders.
Indianapolis-based Eli Lilly will make an initial up-front
payment of 80 million Swiss francs ($80.4 million) to AC Immune,
which is also eligible for CHF60 million in potential near-term
development milestone payments and up to about CHF1.7 billion in
other potential milestones, the companies said.
Eli Lilly also will buy a $50 million note, convertible into an
equity stake in AC Immune, a Lausanne, Switzerland, clinical-stage
biopharmaceutical company.
Eli Lilly and AC Immune SA said they plan to develop tau
aggregation inhibitor small molecules to potentially treat
neurodegenerative diseases such as the memory-robbing disorder
Alzheimer's.
The companies said Eli Lilly will have worldwide
commercialization rights for the inhibitors in the area of
Alzheimer's disease, while AC Immune retains certain development
rights in orphan indications and co-development and co-promotion
options in some indications outside Alzheimer's.
Drug makers have long sought to find a breakthrough treatment
for Alzheimer's, which affects an estimated five million Americans
and tens of millions globally. Current treatments for the brain
disease can alleviate symptoms but don't slow the condition's
underlying progression.
Eli Lilly and AstraZeneca PLC (AZN) in June scrapped two
late-stage trials of an experimental Alzheimer's drug they were
co-developing after the treatment didn't work as well as they had
hoped.
Pfizer Inc. (PFE) in January said it would stop trying to
discover new drugs for Alzheimer's and Parkinson's disease. Axovant
Sciences Ltd. (AXON) and Biogen Inc. (BIIB) have also reported
disappointing results from Alzheimer's research.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 12, 2018 07:04 ET (12:04 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
AC Immune (NASDAQ:ACIU)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
AC Immune (NASDAQ:ACIU)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024